AHA 2023 Late-Breaking Science Lineup Revealed

The American Heart Association has announced eight late-breaking science sessions to be presented in Philadelphia from November 10th to November 13th. AHA is focussed on innovation in cardiovascular disease for scientists, clinicians, researchers and other healthcare professionals.


Among the event’s highlights are eight late-breaking trial sessions, as listed below.


Watch our coverage of last year's event. 


LBS.01. Obesity – Novel Therapeutics and Implications for Population Health


Saturday, 11 November 2023, 08:30am – 09:15am ET


SELECT – Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes – Presented by Dr Abraham Lincoff (CT: NCT03574597)


LBS.02. Hot Topics in Management of Coronary Artery Disease/Acute Coronary Syndrome


Saturday, 11 November 2023, 09:45am – 11:00am ET


MINT - Restrictive versus Liberal Blood Transfusion in Patients with Myocardial Infarction and Anemia: Results of the MINT Trial – Presented by Dr Jefferey Carson (CT: NCT02981407)


ORBITA-2 - Percutaneous Coronary Intervention for Stable Angina: A Randomized, Placebo-Controlled Trial – Presented by Dr Christopher Rajkumar (CT: NCT03742050)


DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patient with Acute Myocardial Infarction Without Diabetes – Presented by Dr Stefan James (CT: NCT04564742)


LBS.03. Heart Failure – VADS, KIDS and Money


Saturday, 11 November, 2023, 1:30pm – 2:45pm ET


ARIES HM3 - Avoidance of Aspirin with Left Ventricular Assist Devices in Advanced Heart Failure: Primary Results of the International, Double-Blind, Placebo-Controlled ARIES HM3 Trial – Presented by Dr Mandeep Metra (CT: NCT04069156)


The TEAMMATE Trial - Everolimus to Prevent Rejections in Children after Cardiac Transplantation – Presented by Dr Christopher Almond (CT: NCT03386539)


Integrating Cost Into Shared Decision-Making for Heart Failure With Reduced Ejections Fraction: A Trial Providing Out-of-Pocket Costs for Heart Failure Medications During Clinical Encounters – Presented by Neal Dickert (CT: NCT04793880)


LBS.04. Using Drugs, Diet and Delivery to Optimize Hypertension Outcomes


Saturday, 11 November, 2023, 3:15pm – 4:30pm ET

CARDIA-SSBP -  Effects of Dietary Sodium on Systolic Blood Pressure in Middle-Aged Individuals: A Randomized Order Cross-Over Trial – Presented by Dr Deepak Gupta (CT: NCT04258332)


POP-HT - Long-Term Blood Pressure Control After Physician Optimised Postpartum Blood Pressure Self-Management: The POP-HT Randomised Clinical Trial – Presented by Dr Paul Leeson (CT: NCT04273854)


KARDIA-1 - Sustained Blood Pressure Reduction with the RNA Interference Therapeutic Zilebesiran: Primary Results from KARDIA-1, a Phase 2 Study in Patients With Hypertension – Presented by Dr George Bakris (CT: NCT04936035)


CRHCP -  Effectiveness of Blood Pressure-Lowering Intervention of Risk of Total Dementia Among Patients with Hypertension: A Cluster-Randomized Effectiveness Trial – Presented by Dr Jiang He


LBS.05. Shocking Decisions in AFib Care


Sunday 12 November, 2023, 08:00am – 09:15am ET


Efficacy and Safety of Dual Direct Current Cardioversion versus Single Direct Ccurrent Cardioversion as an Inital Treatment Strategy in Obese Patients with Atrial Fibrillation – Presented by Dr Joshua Aymond (CT: NCT04539158)


AZALEA-TIMI 71 - Abelacimab, a Novel Factor XI/XIa Inhibitor, vs Rivaroxaban in Patients with Atrial Fibrillation: Primary Results of the AZALEA-TIMI 71 Randomized Trial – Presented by Dr Christian Ruff (CT: NCT04755283)


NOAH-AFNET 6 - Efficacy and Safety of Anticoagulation with Edoxaban in Patients with AHRE Durations > 24 Hours: The NOAH-AFNET 6 Trial – Presented by Dr Nina Becher (CT: NCT02618577)


ARTESIA - Apixaban for the Prevention of Stroke in Patients with Subclinical Atrial Fibrillation – Presented by Dr Jeff Healey (CT: NCT01938248)


LBS.06. Future of Lipid Lowering Therapy – Novel Mechanisms and Approaches


Sunday 12 November, 2023, 3:30pm – 4:45pm ET


REPRIEVE - Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarks in HIV: Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV – Presented by Dr Michael Lu (CT: NCT02344290)


REMAIN- 2 - Recaticimab Add-on Therapy in Patients With Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial – Presented by Dr Xin Du


Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein(a) – Presented by Dr Steven Nissen (CT: NCT05565742)


VERVE-101 - Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol - Interim Results of the Phase 1b heart-1 Trial – Presented by Dr Andrew Bellinger (CT: NCT05398029)


LBS.07. From Local to Global: Achieving Equity in Prevention


Monday 13 November, 2023, 08:00am – 09:15am ET


HTN Program - Hypertension Treatment in Nigeria Program: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial – Presented by Dr Dike Ojji (CT: NCT04158154)


A Cluster Randomized Trial of Automated Referral to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients – Presented by Dr Alexander Fanaroff


ESPRIT - Effects of Intensive Blood Pressure Lowering Treatment in Reducing Risk of Cardiovascular Events – Presented by Dr Jing Li


IMPACTS - Effect of a Multifaceted Implementation Strategy on Blood Pressure Control in Low-Income Patients: A Cluster Randomized Trial – Presented by Dr Jiang He


LBS.08. Artificial Intelligence at the Bedside


Monday 13 November, 09:45 – 11:00am ET


SPEC-AI - Screening for Peripartum Cardiomyopathies Using an Artificial Intelligence Enhanced Digital Stethoscope: A Randomized Clinical Trial – Presented by Dr Demilade Adedinsweo (CT: NCT05438576)


ORFAN - Novel AI Technology to Improve Risk Stratification of Patients Without Obstructive Coronary Artery Disease Undergoing CCTA: The Oxford Risk Factors and Non-Invasive Imaging Study – Presented by Dr Charalambos Antoniades (CT: NCT05169333)


Validation of a Speech Analysis Application to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients – Presented by Dr William Abraham (CT: NCT03266029)


ARISE - Artificial Intelligence Enabled Rapid Identification of ST-Elevation Myocardial Infarction Using Electorcardiogram: A Pragmatic Randomized Controlled Trial – Presented by Dr Chin-Sheng Lin (CT: NCT05118009)